An 'on-eye' UV delivery system for corneal crosslinking can be used safely and effectively to help free presbyopic patients from the need for reading glasses.

The clinical trial is evaluating the TECLens CXLens Crosslinking System, an investigational treatment using ultraviolet (UV) light (375 nm) with riboflavin (vitamin B2) to strengthen and reshape the cornea. By creating controlled biomechanical changes, this study aims to test whether the cornea can be reshaped to reduce refractive errors such as mild myopia or hyperopia in patients of presbyopic age.

Inclusion Criteria:

• Adults aged 40-65 years
• Healthy cornea
• Refractive error between +4.0 D and -5.0 D
• Phakic or monofocal pseudophakic (≥6 months post IOL placement)
• Visual acuity correctable by ±0.25 D

Exclusion Criteria:

• Corneal dystrophy, scarring, or prior corneal crosslinking
• Astigmatism >1.0 D
• Active ocular infection, inflammation, or uncontrolled dry eye
• Advanced glaucoma or diabetic retinopathy
• History of delayed corneal healing
• Pregnancy, breastfeeding, or planning pregnancy during study period
• Certain medications (e.g., isotretinoin)
• Recent participation in other investigational drug/device studies (within 30 days)
• Patients with uncontrolled dry eye or surface disease